Exscientia’s (EXAI) Equal Weight Rating Reiterated at Morgan Stanley

Morgan Stanley restated their equal weight rating on shares of Exscientia (NASDAQ:EXAI) in a research note released on Monday, Benzinga reports. The brokerage currently has a $7.00 price target on the stock.

Separately, Bank of America cut shares of Exscientia from a buy rating to a neutral rating and lowered their price target for the company from $11.00 to $9.00 in a research report on Friday, January 5th.

Exscientia Stock Up 0.2 %

EXAI stock opened at $4.25 on Monday. Exscientia has a fifty-two week low of $4.14 and a fifty-two week high of $9.12. The company has a market capitalization of $513.77 million, a price-to-earnings ratio of -2.87 and a beta of 0.78. The business’s 50 day moving average price is $5.75 and its two-hundred day moving average price is $5.86. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.22 and a current ratio of 6.22.

Exscientia (NASDAQ:EXAI) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02. The company had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $41.63 million. Exscientia had a negative return on equity of 36.44% and a negative net margin of 737.10%. As a group, analysts forecast that Exscientia will post -1.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exscientia

Several hedge funds have recently added to or reduced their stakes in EXAI. GAMMA Investing LLC increased its holdings in shares of Exscientia by 112.1% during the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after acquiring an additional 2,302 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Exscientia by 359.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock valued at $34,000 after purchasing an additional 4,104 shares during the last quarter. Rathbones Group PLC bought a new stake in Exscientia during the 3rd quarter valued at about $47,000. Tocqueville Asset Management L.P. purchased a new position in Exscientia in the third quarter worth about $58,000. Finally, Walled Lake Planning & Wealth Management LLC bought a new position in shares of Exscientia in the fourth quarter worth approximately $64,000. 41.58% of the stock is owned by institutional investors.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.